相关实验视频
Updated: Jan 9, 2026
06:22
Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model
Published on: November 29, 2024
1.3K
达帕格利弗洛辛对慢性心力衰竭进展的关键病理生理路径的影响:DAPA-MODA生物标志物研究
Verónica Martínez-Pina1, Antoni Bayés-Genís2, Julio Nuñez3
1Servicio de Bioquímica Clínica, Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain.
Revista espanola de cardiologia (English ed.)
|November 29, 2025
概括
达帕格利弗洛辛治疗显著降低了关键的心力衰竭生物标志物,如NT-proBNP和MR-proADM. 该药物有利地调节了各种病理生理路径,特别是在基线水平升高的患者中.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 生物标志物研究 生物标志物研究
背景情况:
- 达帕格利弗洛辛改善了慢性心力衰竭 (HF) 的结果,而不管喷射分数.
- 它对反映特定HF病理生理路径的生物标志物的影响需要进一步阐明.
研究的目的:
- 调查达帕格利弗洛辛对慢性HF患者在五个关键病理生理路径中循环生物标志物的影响.
- 了解这些生物标志物的差异化调制由达帕格利弗洛辛.
主要方法:
- 在稳定的慢性HF患者中进行前性,单臂DAPA-MODA生物标记子研究 (n=156).
- 测量11个生物标志物 (心脏应激,炎症,神经激素激活,拥堵,纤维化) 在基线,1个月和6个月.
- 在研究之前,患者接受了优化治疗,不包括SGLT2抑制剂.
主要成果:
- 心肌压力 (NT-proBNP,MR-proANP) 的基线标志物升高,损伤 (热素),炎症 (IL-6,CRP,GDF-15) 和神经内分泌压力 (科普丁).
- 达帕格利弗洛辛在6个月内显著降低了NT-proBNP和MR-proADM.
- 在基线水平升高的患者中观察到MR-proANP,CRP,IL-6,copeptin和PINP的适度降低;ST2和CA-125没有变化;GDF-15增加.
结论:
- 达帕格利弗洛辛对慢性HF的多种病理生理路径产生有利影响.
- 药物对生物标志物的影响是不同的,特别是影响那些在基线上升高的生物标志物.
相关概念视频
01:30Heart Failure V: Medical Management
200
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
200
01:17Pathophysiology of Heart Failure
2.7K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
2.7K
01:29Heart Failure II: Pathophysiology
685
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
685
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
888
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
888
01:22Heart Failure Drugs: Diuretics
768
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
768
01:23Dipeptidyl Peptidase 4 Inhibitors
559
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
559